Stay updated with breaking news from Biocon Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biocon Biologics Ltd, a subsidiary of listed biopharmaceutical company Biocon Ltd, on Tuesday announced the completion of its acquisition of global biosimilars business of its partner Nasdaq listed Viatris Inc.Biocon Biologics and Viatris have ...
Biocon Biologics, a subsidiary of listed biopharmaceutical company Biocon Ltd, on Tuesday announced that it has successfully completed its acquisition of the global biosimilars business of its partner Viatris for USD 3 billion.
Get latest articles and stories on World at LatestLY. According to a statement by the pharma company, Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the US Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors, respectively. World News | Biocon Subsidiary Completes Acquisition of Viatris for USD 3 Billion.
The USFDA has issued a CRL for the Biologics License Application for Insulin Aspart filed by Biocon's partner Viatris.
Biocon Biologics Ltd has entered into a strategic out-licensing agreement with Japanese pharmaceuticals company Yoshindo Inc. for commercializing two of its pipeline biosimilar assets, bUstekinumab and bDenosumab, in the Japanese market.